Jan 12 (Reuters) - The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.


20


Reuters

Latest News

USA Today: Making Meek Mill a temporary NBA celebrity should just be starting point for real change

Daily Mail: Red wine won't improve your health but eating pasta won't make you put on weight

Daily Mail: EastEnders' Max Branning marries sister-in-law Rainie Cross by JIM SHELLEY

Daily Mail: Czech Republic - Factors To Watch on April 25

Daily Mail: Global wind capacity to rise by more than half in next...

Daily Mail: Nikkei falls, Takeda dives on Shire bid; construction...

Daily Mail: Novartis' digital drive continues with eye-disease app

Daily Mail: Global banks fear China will limit JV control through...

Daily Mail: Whitbread to spin off Costa Coffee

NBC New York: Trader Joe's on Upper West Side Sets Opening Date

FOX: Waffle House shooting suspect faces additional warrants, police say

Daily Mail: Video: Huge schools of sharks gather off North Stradbroke Island

FOX: Waffle House shooting suspect faces additional warrants, police say

Reuters: Unjust dessert? Japan demands Koreans wipe map off summit dinner mousse

Daily Mail: About 20 sharks circling off the coast of North Stradbroke IslandĀ filmed by a drone

Daily Mail: Whitbread to split Costa Coffee from group following...

Daily Mail: Lloyds announces profits rise in spite of extra PPI costs

BBC: Scottish Gossip: Rangers, Celtic, Liverpool, Arsenal, Hibs, Hearts, Hull, Hamilton, Partick Thistle

BBC: The Papers: May tells Sturgeon: 'Take it or leave it' on Brexit deal

ABC: AP Exclusive: '93 Amtrak crash survivor relives each new one

Reuters: Britain considers setting up satellite system to rival EU's Galileo

Daily Mail: British lender Metro Bank's Q1 profit jumps

BBC: No female WWE wrestlers at Saudi Arabia show